Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
people with kidney disease, in this paper
Already taking being on metformin at admission, or nottheir own situation, not assigned
on being on metformin at admission
not exposed to metformin
Being on metformin at admission went with lower survival at 28 days−19%
correlation, not a testAlready taking current metformin use, or nottheir own situation, not assigned
on current metformin use
unexposed periods
No clear link with AKI cases−6%
correlation, not a testthe abstract, start to end
… a higher rate of survival at 28 days (HR 0.81, 95% CI 0.69, 0.94, p = 0.006) …
… not associated with AKI incidence, HR 0.94 (95% CI 0.87, 1.02, p = 0.15).
← favours treatmentfavours comparator →
could be chanceSurvival at 28 daysbeing on metformin at admission vs not exposed to metformin, in those with incident AKI
HR 0.810.69–0.94
AKI incidencecurrent metformin use vs unexposed periods
HR 0.940.87–1.02
MetforminAll-cause mortalityKidney outcomes
1 / 4